Piper Sandler lowered the firm’s price target on Cue Biopharma to $3 from $8 and keeps an Overweight rating on the shares. Cue is focusing on autoimmune disease and conducting a corporate restructuring to reduce workforce by 25%, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CUE:
- Cue Biopharma Refocuses on Autoimmune Programs, Restructures Operations
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Cue Biopharma Welcomes Michael J. Fox to Board, Shareholders Vote
- Cue Biopharma presents updated data from Phase 1 trial of CUE-101
- Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting